We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+32.2%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
+$1.12B
(+80%)
Cap. Flow
+$772M
Cap. Flow
% of AUM
30.59%
Top 10 Holdings %
Top 10 Hldgs %
26.22%
Holding
205
New
69
Increased
52
Reduced
26
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$62.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$61M |
| 3 |
Fidelity National Information Services
FIS
|
+$54.2M |
| 4 |
KLA
KLAC
|
+$44.1M |
| 5 |
PayPal
PYPL
|
+$41.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$65.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$46.8M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$46.5M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$41.2M |
| 5 |
Analog Devices
ADI
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.91% |
| 2 | Technology | 35.52% |
| 3 | Communication Services | 5.66% |
| 4 | Consumer Discretionary | 4.26% |
| 5 | Industrials | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JNPR
76
DELISTED
Juniper Networks
JNPR
| $9.38M | 0.37% |
410,337
+148,476
| +57% | +$3.42M |
|
77
PTC Therapeutics
PTCT
$5.68B
| $9.22M | 0.37% |
181,710
-53,576
| -23% | -$2.63M |
|
78
Netflix
NFLX
$299B
| $8.79M | 0.35% |
193,170
+80,590
| +72% | +$3.43M |
|
79
Karyopharm Therapeutics
KPTI
$43.5M
| $8.77M | 0.35% |
+30,882
| New | +$9.13M |
|
80
Akebia Therapeutics
AKBA
$354M
| $8.75M | 0.35% |
644,229
+17,519
| +3% | +$181K |
|
|
P
81
Everpure Inc
P
$25.7B
| $8.29M | 0.33% |
478,261
+247,223
| +107% | +$3.71M |
|
82
Legend Biotech
LEGN
$3.59B
| $8.25M | 0.33% |
+193,857
| New | +$7.57M |
|
|
LPRO
83
DELISTED
Open Lending Corp
LPRO
| $7.75M | 0.31% |
+513,445
| New | +$5.82M |
|
84
BioCryst Pharmaceuticals
BCRX
$2.28B
| $7.58M | 0.3% |
1,590,841
+336,314
| +27% | +$1.34M |
|
|
MTEM
85
DELISTED
Molecular Templates, Inc.
MTEM
| $7.53M | 0.3% |
36,412
+20,316
| +126% | +$4.72M |
|
86
Lumentum
LITE
$55.5B
| $7.5M | 0.3% |
+92,090
| New | +$7.02M |
|
87
T-Mobile US
TMUS
$185B
| $7.21M | 0.29% |
69,217
-76,333
| -52% | -$7.32M |
|
88
Labcorp
LH
$25B
| $7.18M | 0.28% |
50,348
+13,498
| +37% | +$1.87M |
|
|
AKUS
89
DELISTED
Akouos Inc
AKUS
| $7.18M | 0.28% |
+319,013
| New | +$7.11M |
|
90
Mettler-Toledo International
MTD
$28.6B
| $7.1M | 0.28% |
8,814
-1,376
| -14% | -$1.02M |
|
91
Arcturus Therapeutics
ARCT
$164M
| $6.92M | 0.27% |
+148,083
| New | +$5.1M |
|
|
SWTX
92
DELISTED
SpringWorks Therapeutics
SWTX
| $6.83M | 0.27% |
162,515
-48,378
| -23% | -$1.72M |
|
|
HRC
93
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $6.48M | 0.26% |
59,041
-27,616
| -32% | -$2.89M |
|
94
TG Therapeutics
TGTX
$7.96B
| $6.48M | 0.26% |
+332,652
| New | +$5.36M |
|
95
Prothena Corp
PRTA
$425M
| $6.28M | 0.25% |
600,778
+175,862
| +41% | +$1.95M |
|
|
MRSN
96
DELISTED
Mersana Therapeutics
MRSN
| $6.25M | 0.25% |
+10,686
| New | +$3.65M |
|
97
Encompass Health
EHC
$11B
| $6.23M | 0.25% |
126,418
-10,469
| -8% | -$565K |
|
98
Meta Platforms (Facebook)
META
$1.42T
| $6.09M | 0.24% |
+26,825
| New | +$5.6M |
|
|
PARA
99
DELISTED
Paramount Global Class B
PARA
| $6.08M | 0.24% |
+260,653
| New | +$5.02M |
|
100
Nokia
NOK
$51B
| $6.06M | 0.24% |
1,377,725
+311,953
| +29% | +$1.18M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Woodline Partners held 205 positions worth $2.52B, up 80% from $1.4B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Woodline Partners deployed $772M of net new capital in Q2 2020, opening 69 new positions and adding to 52 existing holdings. Its largest new stake was Johnson & Johnson: 418,880 shares worth $58.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 46% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $41.2M trimmed.
- Woodline Partners's largest Q2 2020 buy was Johnson & Johnson: 418,880 shares worth $58.9M.
- Woodline Partners added most to Intel in Q2 2020, an estimated $62.5M increase.
- Woodline Partners's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $41.2M.
- Woodline Partners fully exited Pfizer in Q2 2020, selling an estimated $65.7M.
- Woodline Partners's ten largest holdings make up 26% of its $2.52B portfolio in Q2 2020.
- Woodline Partners opened 69 new positions and closed 58 in Q2 2020.
- Woodline Partners's portfolio value rose 80% quarter-over-quarter to $2.52B.
Based on Woodline Partners's 13F filing for Q2 2020, filed 14 Aug 2020.